A phase I study of ADI-001 in patients with Anti-neutrophil-cytoplasmic-antibody-associated-vasculitis
Latest Information Update: 05 Mar 2025
At a glance
- Drugs ADI-001 (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions
Most Recent Events
- 27 Feb 2025 According to an Adicet media release, Patient enrollment is expected to be initiated in the second quarter of 2025.
- 19 Sep 2024 According to an Adicet media release, initial clinical data expected in the first half of 2025.
- 13 Sep 2024 New trial record